Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Poor oral health (periodontal disease) impacts nearly 51% of Indians
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
The company will also share results in two additional posters for deuruxolitinib
Subscribe To Our Newsletter & Stay Updated